Statera Biopharma (NASDAQ:STAB) & Orgenesis (NASDAQ:ORGS) Head-To-Head Contrast

Earnings & Valuation

This table compares Statera Biopharma and Orgenesis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Statera Biopharma	N/A	N/A	N/A	($0.07)	0.00
Orgenesis	$662,000.00	2.05	-$55.36 million	($7.13)	-0.04

Statera Biopharma has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Statera Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Statera Biopharma has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.16, indicating that its stock price is 216% more volatile than the S&P 500.

Profitability

This table compares Statera Biopharma and Orgenesis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Statera Biopharma	N/A	N/A	N/A
Orgenesis	-3,827.81%	N/A	-130.18%

Institutional & Insider Ownership

22.6% of Orgenesis shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by company insiders. Comparatively, 5.7% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

About Statera Biopharma

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.

About Orgenesis

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.